Skip to content
Vedanta Biosciences receives fast track designation for VE303 and presents phase 2 data at digestive disease week
We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.OkI do not consent